Exploring long-acting HIV prevention for women who inject drugs
Exploring Engagement and Opportunities to Optimize CAB-LA As Pre-exposure Prophylaxis (PrEP) for Women Who Inject Drugs
Drexel University · NCT05799339
This study is trying to understand how women who inject drugs feel about using a long-acting HIV prevention shot and how it compares to taking a daily pill.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 144 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Drexel University (other) |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT05799339 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather essential information to enhance the engagement of women who inject drugs (WWID) in using cabotegravir, a long-acting injectable form of pre-exposure prophylaxis (PrEP) for HIV prevention. It will assess WWID's perceptions of CAB-LA, their decision-making processes regarding its initiation, and compare adherence and care engagement between those using CAB-LA and daily oral PrEP. The study will involve semi-structured interviews and data analysis from electronic medical records over a six-month period, focusing on the unique experiences and challenges faced by this population. The findings will inform future strategies to improve PrEP uptake and adherence among WWID.
Who should consider this trial
Good fit: Ideal candidates for this study are HIV-negative cisgender women aged 18 and older who have used non-prescription injection drugs in the past six months.
Not a fit: Patients who are not HIV-negative or do not meet the criteria of being cisgender women who inject drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved HIV prevention strategies tailored for women who inject drugs.
How similar studies have performed: While this approach is novel in its specific focus on WWID, similar studies have shown promise in improving PrEP uptake and adherence in other populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * HIV-negative cisgender female * age ≥ 18 years * speaks/reads English * reporting past 6 months day non-prescription injection drug use * enrolled in the TIARAS trial (NCT05192434) Exclusion Criteria: • Unable to provide informed consent
Where this trial is running
Philadelphia, Pennsylvania
- Prevention Point Philadelphia — Philadelphia, Pennsylvania, United States (RECRUITING)
Study contacts
- Principal investigator: Alexis M Roth, PhD, MPH — Drexel University
- Study coordinator: Alexis M Roth, PhD, MPH
- Email: amr395@drexel.edu
- Phone: 317-213-3960
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: HIV Infections, Opioid Use, Trauma, Psychological, PrEP, Preexposure Prophylaxis, WWID, Women who inject drugs, CAB-LA